The first injectable PrEP was cabotegravir, made by ViiV Healthcare and approved by America's Food and Drug Administration (FDA) in 2021.

第一个可注射的 PrEP 是卡博特韦，由 ViiV Healthcare 生产， 并于 2021 年获得美国食品药品监督管理局 (FDA) 的批准。

Two recent studies found that cabotegravir injections given every two months were better than daily Truvada pills for keeping uninfected people from catching the virus.

最近的两项研究发现，在防止未受感染的人从受感染的性伴侣那里感染病毒方面，每两个月注射卡波特格雷韦比每天服用特鲁瓦达药片效果更好。

The agency also approved a pill version of cabotegravir to be taken with rilpivarine for one month to ensure the drugs do not cause bad effects.

该机构还批准了一种片剂卡波特格雷韦，与利匹韦林一起服用一个月，以确保药物不会造成不良影响。